Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Progenra Announces the Promotion of Marc Hixson to its Business Development DepartmentProgenra, Inc., today announced the promotion of Marc Hixson to Sr. Director, Business Development.
By: Marc Hixson Educated at the University of Pittsburgh (AB) and The Pennsylvania State University (MBA), Mr. Hixson brings to Progenra solid experience in pharmaceutical industry sales, business development and operational support. He has led sales, training and market analysis teams and negotiated formulary positions for various pharmaceutical organizations. Before joining Progenra he built a managed markets division for Onset Dermatologics, developing and implementing the company’s strategic direction and guidance on formulary positioning for their product portfolio. “Marc brings us years of experience in business development along with a great understanding of the ubiquitin pathway’s involvement in disease. He will play a critical role as Progenra evolves into a full service pharmaceutical company,” said Dr. Tauseef Butt, President & CEO of Progenra. About Progenra, Inc. Founded in 2002, Progenra is focused on discovery and development of medicines by targeting the ubiquitin pathway, which plays a role in numerous therapeutic areas. Progenra believes that by selectively targeting specific enzymes within this pathway, the degradation of a specific protein or limited family of proteins can be modified, thus avoiding issues which occur if one blocks all protein degradation with the proteasome, thus limiting the side effects. To date Progenra has identified compounds that are in pre-clinical development for a variety of diseases. The company’s intellectual property portfolio underscores Progenra’s commitment to both its technology platform development and drug discovery in the ubiquitin field. For further information please contact: Marc Hixson Progenra Inc. hixson@progenra.com 215.834.3583 http://www.progenra.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|